Trivedi Global, Inc., Henderson, NV, USA.
Trivedi Science Research Laboratory Pvt. Ltd., Thane, Maharashtra, India.
Inflammopharmacology. 2022 Feb;30(1):225-232. doi: 10.1007/s10787-021-00901-z. Epub 2022 Jan 8.
The study objective was to evaluate the therapeutic effect of cannabidiol (CBD) on a combination of caecal slurry, lipopolysaccharide (LPS), and Escherichia coli (E. coli)-induced systemic inflammatory response syndrome (SIRS) in male Sprague Dawley rats.
The therapeutic activity was monitored in behavioral tests and inflammatory biomarkers by the enzyme-linked immune sorbent assay (ELISA) method.
Behavioral tasks were significantly increased like a tail flick response by 73.84% (p ≤ 0.001), grip strength by 33.56% (p ≤ 0.028), locomotor activity by 20.71% (p = 0.034) in the CBD (60 mg/kg) group compared to disease control (DC) group. Levels of inflammatory serum biomarkers like interleukin-1β (IL-1β), matrix metallopeptidase-9 (MMP-9), IL-6, and tumor necrosis factor-alpha (TNF-α) were significantly decreased by 29.56 (p = 0.041), 71.20 (p ≤ 0.001), 35.05 (p ≤ 0.001), and 75.56% (p = 0.002), respectively, in the CBD-60 compared with DC. Inflammatory cytokines levels, viz. IL-1β, MMP-9, IL-6, and TNF-α, in the liver were significantly (p ≤ 0.001) decreased by 81.01, 40.41, 22.84, and 69.46%, respectively, in CBD-60 to DC. Similarly, levels of inflammatory cytokines such as IL-1β and MMP-9 in the kidney were significantly (p ≤ 0.001) decreased by 80.90 and 43.93%, respectively, in CBD-60 compared to DC.
Taken together, results suggest that CBD treatment significantly improved behavioral tasks and decreased the level of inflammatory cytokines under SIRS conditions that might provide an opportunity to manage acute and chronic inflammatory disorders.
本研究旨在评估大麻二酚（CBD）对盲肠内容物、脂多糖（LPS）和大肠杆菌（E. coli）诱导的雄性 Sprague Dawley 大鼠全身炎症反应综合征（SIRS）的治疗作用。
通过酶联免疫吸附试验（ELISA）方法，在行为测试和炎症生物标志物中监测治疗活性。
与疾病对照组（DC）相比，CBD（60mg/kg）组的行为任务明显增加，如尾部摆动反应增加 73.84%（p≤0.001），握力增加 33.56%（p≤0.028），运动活性增加 20.71%（p=0.034）。炎症血清生物标志物水平，如白细胞介素-1β（IL-1β）、基质金属蛋白酶-9（MMP-9）、IL-6 和肿瘤坏死因子-α（TNF-α），分别降低 29.56%（p=0.041）、71.20%（p≤0.001）、35.05%（p≤0.001）和 75.56%（p=0.002）。在 CBD-60 与 DC 相比，肝脏中炎症细胞因子水平，如 IL-1β、MMP-9、IL-6 和 TNF-α，分别显著降低 81.01%、40.41%、22.84%和 69.46%。同样，在 CBD-60 与 DC 相比，肾脏中炎症细胞因子如 IL-1β和 MMP-9 的水平也显著降低（p≤0.001），分别降低 80.90%和 43.93%。
综上所述，CBD 治疗可显著改善 SIRS 状态下的行为任务，降低炎症细胞因子水平，为治疗急性和慢性炎症性疾病提供了机会。
